These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 18673142)

  • 1. 3D-QSAR CoMFA and CoMSIA study on benzodipyrazoles as cyclin dependent kinase 2 inhibitors.
    Dessalew N; Singh SK
    Med Chem; 2008 Jul; 4(4):313-21. PubMed ID: 18673142
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 3D-QSAR CoMFA study on indenopyrazole derivatives as cyclin dependent kinase 4 (CDK4) and cyclin dependent kinase 2 (CDK2) inhibitors.
    Singh SK; Dessalew N; Bharatam PV
    Eur J Med Chem; 2006 Nov; 41(11):1310-9. PubMed ID: 16890327
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular modeling studies to characterize N-phenylpyrimidin-2-amine selectivity for CDK2 and CDK4 through 3D-QSAR and molecular dynamics simulations.
    Chohan TA; Chen JJ; Qian HY; Pan YL; Chen JZ
    Mol Biosyst; 2016 Apr; 12(4):1250-68. PubMed ID: 26883408
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 3D-QSAR and docking studies on pyrazolo[4,3-h]qinazoline-3-carboxamides as cyclin-dependent kinase 2 (CDK2) inhibitors.
    Lan P; Chen WN; Xiao GK; Sun PH; Chen WM
    Bioorg Med Chem Lett; 2010 Nov; 20(22):6764-72. PubMed ID: 20869873
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular modeling studies of 4,5-dihydro-1H-pyrazolo[4,3-h] quinazoline derivatives as potent CDK2/Cyclin a inhibitors using 3D-QSAR and docking.
    Ai Y; Wang ST; Sun PH; Song FJ
    Int J Mol Sci; 2010 Sep; 11(10):3705-24. PubMed ID: 21152296
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular Modeling and Design Studies of Purine Derivatives as Novel CDK2 Inhibitors.
    Zhang G; Ren Y
    Molecules; 2018 Nov; 23(11):. PubMed ID: 30423939
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An in silico exploration of the interaction mechanism of pyrazolo[1,5-a]pyrimidine type CDK2 inhibitors.
    Li Y; Gao W; Li F; Wang J; Zhang J; Yang Y; Zhang S; Yang L
    Mol Biosyst; 2013 Sep; 9(9):2266-81. PubMed ID: 23864105
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 3D-QSAR CoMFA study on oxindole derivatives as cyclin dependent kinase 1 (CDK1) and cyclin dependent kinase 2 (CDK2) inhibitors.
    Singh SK; Dessalew N; Bharatam PV
    Med Chem; 2007 Jan; 3(1):75-84. PubMed ID: 17266627
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 2D and 3D-QSAR analysis of pyrazole-thiazolinone derivatives as EGFR kinase inhibitors by CoMFA and CoMSIA.
    Pourbasheer E; Aalizadeh R; Shiri HM; Banaei A; Ganjali MR
    Curr Comput Aided Drug Des; 2015; 11(4):292-303. PubMed ID: 26548551
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 3D QSAR pharmacophore, CoMFA and CoMSIA based design and docking studies on phenyl alkyl ketones as inhibitors of phosphodiesterase 4.
    Gaurav A; Singh R
    Med Chem; 2012 Sep; 8(5):894-912. PubMed ID: 22741782
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined 3D-QSAR modeling and molecular docking study on 1,4-dihydroindeno[1,2-c]pyrazoles as VEGFR-2 kinase inhibitors.
    Zeng H; Zhang H
    J Mol Graph Model; 2010 Aug; 29(1):54-71. PubMed ID: 20471293
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Computational Analysis of CRTh2 receptor antagonist: A Ligand-based CoMFA and CoMSIA approach.
    Babu S; Sohn H; Madhavan T
    Comput Biol Chem; 2015 Jun; 56():109-21. PubMed ID: 25935115
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 3D-QSAR and molecular docking studies on pyrazolopyrimidine derivatives as glycogen synthase kinase-3beta inhibitors.
    Dessalew N; Patel DS; Bharatam PV
    J Mol Graph Model; 2007 Mar; 25(6):885-95. PubMed ID: 17018257
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Insight into the structural requirements of urokinase-type plasminogen activator inhibitors based on 3D QSAR CoMFA/CoMSIA models.
    Bhongade BA; Gadad AK
    J Med Chem; 2006 Jan; 49(2):475-89. PubMed ID: 16420035
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 3D-QSAR and molecular docking study on bisarylmaleimide series as glycogen synthase kinase 3, cyclin dependent kinase 2 and cyclin dependent kinase 4 inhibitors: an insight into the criteria for selectivity.
    Dessalew N; Bharatam PV
    Eur J Med Chem; 2007 Jul; 42(7):1014-27. PubMed ID: 17335939
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CoMFA and CoMSIA analyses on 1,2,3,4-tetrahydropyrrolo[3,4-b]indole and benzimidazole derivatives as selective CB2 receptor agonists.
    Cichero E; Cesarini S; Mosti L; Fossa P
    J Mol Model; 2010 Sep; 16(9):1481-98. PubMed ID: 20174844
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular modelling studies on cinnoline-based BTK inhibitors using docking and structure-based 3D-QSAR.
    Li R; Du Y; Shen J
    SAR QSAR Environ Res; 2018 Nov; 29(11):847-873. PubMed ID: 30280589
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 3D-QSAR and molecular docking studies on fused pyrazoles as p38α mitogen-activated protein kinase inhibitors.
    Lan P; Huang ZJ; Sun JR; Chen WM
    Int J Mol Sci; 2010 Sep; 11(9):3357-74. PubMed ID: 20957100
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CoMFA, CoMSIA, Topomer CoMFA, HQSAR, molecular docking and molecular dynamics simulations study of triazine morpholino derivatives as mTOR inhibitors for the treatment of breast cancer.
    Chhatbar DM; Chaube UJ; Vyas VK; Bhatt HG
    Comput Biol Chem; 2019 Jun; 80():351-363. PubMed ID: 31085426
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 3D-QSAR, molecular dynamics simulations, and molecular docking studies on pyridoaminotropanes and tetrahydroquinazoline as mTOR inhibitors.
    Chaube U; Bhatt H
    Mol Divers; 2017 Aug; 21(3):741-759. PubMed ID: 28577112
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.